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Summary We have analysed the contribution of several parameters, e.g. drug accumulation, MDR] P-
glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and topoisomerase (topo) II, to drug
resistance in a large set of drug-resistant variants of the human non-small-cell lung cancer cell line SW-1573
derived by selection with low concentrations of doxorubicin or vincristine. Selection with either drug nearly
always resulted in MDR clones. The resistance of these clones could be explained by reduced drug accumula-
tion and was associated with a decrease rather than an increase in the low MDRJ mRNA level. To test
whether a decrease in MDRJ mRNA indirectly affected resistance in these cells, we introduced a MDRI-
specific hammerhead ribozyme into wild-type SW-1573 cells. Although this led to a substantial reduction in
MDR] mRNA, it did not result in resistance. In all resistant clones we found an altered form of the multidrug
resistance-associated protein (MRP), migrating slightly slower during SDS-polyacrylamide gel electrophoresis
than MRP in parental cells. This altered MRP was also present in non-P-gp MDR somatic cell hybrids of the
SW-1573 cells, demonstrating a clear linkage with the MDR phenotype. Treatment ofcrude cellular membrane
fractions with N-glycanase, endoglycosidase H or neuraminidase showed that the altered migration of MRP
on SDS-PAGE is due to a post-translational modification. There was no detectable difference in sialic acid
content. In most but not all doxorubicin-selected clones, this MDR phenotype was accompanied by a
reduction in topo IIx mRNA level. No reduction was found in the clones selected with vincristine. We
conclude from these results that selection of the SW-1573 cell line for low levels of doxorubicin or vincristine
resistance, predominantly results in MDR with reduced drug accumulation associated with the presence of an
altered MRP protein. This mechanism can be accompanied by other resistance mechanisms, such as reduced
topo IIa mRNA in case of doxorubicin selection.
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Selection of the human non-small-cell lung cancer cell line
SW-1573 for resistance to doxorubicin can result in two types
of multidrug resistance (MDR): high-level resistance due to
P-glycoprotein encoded by the MDR1 gene (Baas et al.,
1990), a well-defined form of MDR (reviewed by Endicot
and Ling, 1988; Roninson, 1991; Schinkel and Borst, 1991;
Gottesman and Pastan, 1993; Moscow et al., 1993); and
low-level resistance associated with a complex phenotype that
includes a decrease rather than an increase in MDR1 expres-
sion, a decrease in topoisomerase (topo) IIa mRNA and a
decreased drug uptake (Eijdems et al., 1992). This form of
non-P-gp MDR was first identified in three independent SW-
1573 mutants (Keizer et al., 1989; Baas et al., 1990; Kuiper et
al., 1990) and it results in resistance to drugs affecting the
function of topoisomerase II (topo II) such as daunorubicin,
VP16-213 and m-AMSA [4'-(9-acridinylamino)methanesul-
phon-m-anisidine], to the membrane-active compound grami-
cidin D and to drugs affecting the polymerisation of
microtubules such as the vinca alkaloids and colchicine
(Keizer et al., 1989; Baas et al., 1990; Kuiper et al., 1990;
Eijdems et al., 1992). In somatic cell fusions we have shown
that the MDR phenotype, the reduced drug accumulation
and the reduction in MDR1 P-gp mRNA are transferred
together to drug-sensitive SW-1573 cells, but that the altera-
tion in topo IIa is not genetically linked to the non-P-gp
MDR phenotype (Eijdems et al., 1992).
Several other non-P-gp MDR cell lines have been selected
(reviewed in Cole, 1992) and are being used to identify the
mechanism(s) underlying this form of resistance. Cole et al.
(1992), identified the multidrug resistance-associated protein
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(MRP) gene, which was amplified and overexpressed in one
of these non-P-gp MDR cell lines, H69AR. Subsequently,
overexpression of the MRP gene was reported in other non-
P-gp MDR cell lines (Krishnamachary and Center, 1993;
Slovak et al., 1993; Zaman et al., 1993; Barrand et al., 1994;
Schneider et al., 1994), suggesting a role for MRP, a member
of the ATP-binding cassette transporter superfamily, in these
cell lines as well. Recent transfection studies have proved that
MRP can confer resistance to a broad range of natural
product drugs (Grant et al., 1994; Zaman et al., 1994) by
extruding the drugs from the cells (Zaman et al., 1994).
Since the multiplicity of alterations in the SW-1573 non-P-
gp MDR cell lines described thus far remains puzzling, we
have isolated a series of new resistant variants with drug
concentrations just above the ICIO of the parental cell line to
study the following questions:
(1) What is the predominant form of drug resistance
obtained by low-level drug selection?
(2) Are known transporters such as MDR1 P-glycoprotein
or MRP involved in the low-level MDR present in the
resistant variants?
(3) Is down-regulation of MDRJ mRNA an obligatory
feature of low-level MDR in these variants?
(4) Is the observed resistance frequently associated with a
decrease in topo IIa mRNA level?
(5) Does vincristine and doxorubicin selection result in the
same resistance phenotype?
Material and methods
Chemicals
Doxorubicin (doxorubicin hydrochloride), vincristine sul-
phate, ouabain and digitonin (50% pure) were purchased
from Sigma (St Louis, MO, USA), daunorubicin hydroch-
loride was obtained from Specia (Paris, France), [G-3H]vincristine sulphate (sp. act. 4.8 Ci mmol-1) from Amer-
sham (UK) and [G-3H]daunorubicin (sp. act. 1.6 Ci mmol-')
from DuPont de Nemours (Germany).
Cell culture
The resistant cell lines described in this study were derived
from the human non-small-cell lung cancer cell line SW-1573,
originally isolated and characterised by Dr A Leibovitz
(Scott and White Clinic, Temple, TX, USA). Cell line Slou is
a subclone of the drug-sensitive parental cell line SI (a
SW-1573 subline which was morphologically homogeneous)
transfected with the xl subunit of the murine sodium/
potassium exchanger (Eijdems et al., 1992). This clone has
similar growth characteristics and drug sensitivity as the
original SW-1573 S1 cell line. The sensitivity for MDR drugs
was also unaffected by the presence of ouabain in the culture
medium. The non-P-gp MDR cell line 1R50b was isolated
from the drug-sensitive parental cell line SI by a multistep
doxorubicin selection up to 50 nM (Keizer et al., 1989; Baas
et al., 1990; Kuiper et al., 1990), whereas cell line 5R30 was
isolated by a single step at 30 nM doxorubicin as a single-cell
clone. In this study, we decided to use a transfected single-
cell subclone of SI to exclude the possibility that we would
select pre-existing MDR variants that might be present at a
very low frequency in the original SI cell line. All drug
resistance assays and initial drug selection were performed in
the absence of ouabain. After selection, MDR clones were
tested for resistance to ouabain, to ascertain that the MDR
clones were derived from Slou. Resistant cell lines were
isolated as single-cell clones from cell line Slou in a single
step at 25 nM, 30 nM and at 40 nM doxorubicin or at 20 nM
and at 25 nM vincristine. For nomenclature we took the drug
concentration (nM) used for selection followed by an unique
clone number that is preceded by a 'V' when the clones were
selected with vincristine. When the growth rate of the
selected clones was similar to that of the parental cells with-
out drug they were analysed. To generate stable transfectants
containing the MDRJ-specific hammerhead ribozyme, drug-
sensitive S1 cells were transfected with the 196 MDR]
ribozyme construct with linked neomycin resistance marker,
designed by Kobayashi et al. (1993), following a standard
calcium phosphate precipitation technique (Graham and Van
der Eb, 1973). Control transfections were performed with
pGEM3Zf(-) DNA. After 3 weeks of selection with G-418
(800 ygml-'), individual clones were picked and propagated
separately under G-418 selection. All cells were grown as
monolayers in Ham's F-l0 medium (Gibco, Paisley, UK)
supplemented with 10% fetal calf serum, 2 mM glutamine,
penicillin (50 units ml-l) and streptomycin (50figml-'). Cells
were maintained in humidified air/5% carbon dioxide at
37'C. All cells were free of Mycoplasma as tested by the use
of the Gen-Probe rapid Mycoplasma detection system (Gen-
Probe, San Diego, CA, USA).
Assay ofdrug resistance
Clonogenic survival assays were carried out as follows: cells
were plated at 80 cells per well in 24-well dishes (tissue
culture cluster 3424; Costar, Cambridge, MA, USA) in the
continuous presence of an increasing concentration of drugs.
Cells were grown for 8 days, fixed and stained with 0.2%
crystal violet (merck 820603) in 3.7% glutaraldehyde. The
percentage of cells that were able to produce a colony of
> 50 cells was used as a measure of cell survival. The resis-
tance was calculated as the ratio of IC,O of the resistant cell
line to the IC,O of the parental cell line.
Cellular drug accumulation
Steady-state accumulation of drugs was measured according
to Skovsgaard (1990), modified by Broxterman et al. (1988).
Adherent cells in the logarithmic phase of growth were tryp-
sinised, washed and resuspended at densities of 0.2-0.5 x 106
cells ml-' (daunorubicin) or 0.5 -1.5 x 106 cellsml1' (vincris-
Altered MRP is associated with MDR
EWHM Eijdems etal M
299
tine) in Dulbecco's modified essential medium (DMEM)
without bicarbonate containing 20 mM N-2-hydroxyethyl-
piperazine-N'-2ethanesulphonic acid (Hepes), 10% fetal calf
serum (pH 7.35 ± 0.05) and divided into 0.5 ml portions. [G-
3H]vincristine (diluted with unlabelled vincristine to a vincris-
tine concentration of 0.5tLM) or [G-3H]daunorubicin (diluted
with unlabelled daunorubicin to a daunorubicin concentra-
tion of 0.5pM) was added and cells were incubated at 370C
for 60 min. In the same experiment the daunorubicin
accumulation was compared with maximal daunorubicin
binding to the cells upon permeabilisation of the plasma
membrane with digitonin (Versantvoort et al., 1992).
Digitonin (20JAM) was added 5 min before the end of the
incubation time with daunorubicin. Drug uptake was stopped
by addition of ice-cold phosphate-buffered saline (PBS), sup-
plemented with 10% growth medium, and after two cold
washes the cells were transferred to liquid scintillation fluid
Opti-Phase III (LKB, Bromma, Sweden) and radioactivity
was measured. Values were corrected for the amount of
cell-associated radioactivity at time zero at 0°C.
RNAseprotection assay
Cytoplasmic RNA was isolated by a Nonidet P-40 lysis
procedure (Sambrook et al., 1989). The RNAse protection
was carried out according to Zinn et al. (1983) modified by
Baas et al. (1990). Ten micrograms of total cytoplasmic RNA
from each SW-1573 derivative was used or 10 g of
Escherichia coli tRNA as a negative control (Boehringer
Mannheim, Germany). The protected probe was visualised
by electrophoresis through a denaturing 6% acrylamide gel
containing 8 M urea, followed by autoradiography. The fol-
lowing probes were used: MDRJ, a 301 nucleotide MDR]
cDNA fragment (nucleotide positions 3500-3801; Chen et
al., 1986); topo IIa, a 174 nucleotide topo IIm cDNA frag-
ment (nt positions 1343-1517; Tsai-Pflugfelder et al., 1988);
MRP, a 244 nucleotide MRP cDNA fragment (nucleotide
positions 239-483; Zaman et al., 1993). In all experiments a
probe for y-actin (Enoch et al., 1986) was included as an
internal control. To determine the intensity of the signals for
MDRJ, topo IIa, MRP and y-actin mRNA bands, the
autoradiographs were scanned on a Bioimage analysis system
(Millipore, USA).
Protein immunoblot analysis
Total cell lysates were made by lysis of cells in 10 mM
potassium chloride, 1.5 mM magnesium chloride, 10 mM
Tris-HCI pH 7.4 and 0.5% (w/v) sodium dodecyl sulphate
(SDS) supplemented with 1 mM phenylmethylsulphonyl fluor-
ide (PMSF), leupeptide (2 tgml-'), pepstatin (1 ygml-') and
aprotinin (2pgml-'). DNA was sheared by sonication.
Crude cellular membrane fractions were prepared as
described previously (Gerlach et al., 1987) and protein con-
centrations were measured using the Bio-Rad protein assay
(Bio-Rad, Richmond, CA, USA). The protein samples were
dissolved in sample buffer [65mM Tris-HCI pH6.8, 2.5%
(w/v) SDS, 5% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol],
separated on a 7.5% (w/v) polyacrylamide gel containing
0.1% (w/v) SDS and transferred onto nitrocellulose paper
(Schleicher and Schuell, Dassel, Germany) by electroblotting.
The blots were probed with the monoclonal anti-MRP
antibody, MRPrl, raised against a bacterial fusion protein
containing amino acids 192-360 of MRP (Flens et al., 1994).
Antibody was visualised with peroxidase-conjugated rabbit
anti-rat immunoglobulins (Dako, Copenhagen, Denmark)
followed by enhanced chemiluminescence detection (Amer-
sham, UK).
Analysis ofprotein-linked oligosaccharides
For the removal of N-linked oligosaccharides, crude cellular
membrane fractions were incubated with 2.67 mUJAl-' N-
glycanase (a mixture of endoglycosidase F and peptide-N-
glycosidase F; Boehringer Mannheim, Mannheim, Germany)Altered MRP is associated with MDR x EWHM Eijdems etal
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overnight at 30°C as described previously (Schinkel et al.,
1993). High-mannose oligosaccharides were removed by
incubation of the crude cellular membrane fractions with
2 units ml- endoglycosidase H (Endo H; Boehringer Mann-
heim, Mannheim, Germany) in sodium citrate pH 5.5 (end
concentration 50 mM) and 0.2% (w/v) SDS. Incubations were
performed overnight at 37°C. For the removal of sialic acids,
crude cellular membrane fractions were incubated with
1Ounits ml-' neuraminidase (type 8) overnight at 4°C.
Results
MDR isfrequently selected with low levels ofdoxorubicin
SW-1573 clones, resistant to low levels of doxorubicin, were
isolated in a single-step procedure using 25 nM, 30 nM and
40 nM doxorubicin (ICIo of the parental cells is 15 nM). After
3 months ofselection, 34 clones were isolated and cultured in
the presence of doxorubicin. All clones were analysed for
their level of mRNA for MDRI P-gp and topo IIa (see
Figure 1) and a representative subset of ten clones was
chosen and analysed in detail. As expected, all ten clones
showed significant resistance to doxorubicin (Table I). With
the exception of clone 5R30, all clones also showed some
degree of vincristine resistance (Table I). We conclude that
most clones have a MDR phenotype of the non-P-gp variety,
as MDRJ mRNA is reduced rather than elevated in most of
them (see below).
Drug accumulation is reduced in the doxorubicin-selected
SW-1573 clones
To investigate whether drug resistance correlated with
reduced drug accumulation in these cell lines, daunorubicin
and vincristine accumulation was determined (Table II). All
but two of the doxorubicin-selected clones (25.26 and 40.8)
showed a reduced steady-state accumulation of daunorubicin
compared with the drug-sensitive parental cell line (Table II).
In most clones this accumulation defect for daunorubicin was
due to a drug gradient over the plasma membrane because
the drug uptake increased after permeabilisation of the cell
membrane by digitonin (Table III). Despite the lack of an
apparent daunorubicin accumulation defect, clone 40.8
showed a significant increase of drug accumulation in the
presence of digitonin. No significant differences were found
Table I Drug resistance in the SW-1573 clones selected at a low
doxorubicin or vincristine concentration
Resistancefactor (RF)a.b Doxorubicin RF/
Cell line Doxorubicin Vincristine vincristine RF
Doxorubicin-selected
25.10 2.3 + 0.7 (4)C 1.7 ± 0.4 (4)C 1.35
25.26 6.5 ± 1.3 (4)C 3.2 ± 1.1 (5)C 2.03
5R30 4.4 0.1 (2)c 1.1 0.1 (2) 4.00
30.3A 2.4 ± 0.7 (3)C 3.0 ± 2.0 (3) 0.80
30.10 3.7 1.4 (3)c 2.4 0.9 (3) 1.54
30.12 3.2 0.9 (3)c 3.4 1.4 (4)c 0.94
30.14 4.3 1.6 (4)C 3.0 1.2 (5)C 1.43
40.3 4.8 ± 1.5 (3)C 2.8 ± 0.9 (4)C 1.71
40.8 4.2 1.7 (4)c 2.2 0.8 (3) 1.91
40.10 3.6± 1.5 (3)C 2.8± 1.0 (4)C 1.28
lR5Obd 6.1 0.9 (5)C 3.1 0.8 (8)c 1.96
30.3M 3.7 1.2 (3)C 4.6 1.0 (3)c 0.80
Vincristine-selected
20V1 3.1 ± 1.0 (3)C 10.6 ± 1.0 (3)C 0.29
20V2 3.0 ± 0.8 (3)C 9.9 ± 2.1 (3)C 0.30
20V5 2.9 ± 0.2 (3)C 10.1 ± 2.5 (3)C 0.29
25V3 2.9 ± 0.8 (3)C 10.3 ± 1.3 (3)C 0.28
25V4 2.9 0.7 (3)c 12.2 1.8 (3)c 0.24
25V5 2.9 ± 0.9 (3)C 12.9 ± 1.1 (3)C 0.22
aThe resistance factor =IC,O cell line/IC,0 parental cell line (IC,O
parental cell line S1 = ICIo parental cell line Slou). "The data are the
mean resistance factor ± s.d. or the range in case of two experiments.
The number of experiments (clonogenic survival assay) is in
parentheses. Each experiment was performed in duplicate. 'The
resistance factor differs significantly from the resistance factor of the
parentalcell lineswith atleast95% confidence. dResults fortheoriginal
non-P-gp MDR cell line IR50b are also shown.
1bU 25 nM
Lnh Hrnm IN- - - ID ID-
b _ _ N N N N X
b
0 qt 00 C') 14 (0 q
r- r- v- C,4 " 04 CC')
120
90
60
30
120
90
60
30
30 nM
[Ilrlihf1 rH n n .
IX O N * MM N MOWD 00 (N O
v- V-- q-. - w- N N N N N m C X
iri-h Hnn---
4 0 C4 10 0 (N- 0
In
Figure 1 MDR] P-glycoprotein and topoisomerase IlIamRNA levels measured by RNAse protection assays. (a) MDR] mRNA
levels. (b) Topoisomerase IIx mRNA levels. Clones are grouped by doxorubicin concentration used for selection. The identifying
numbers of the clones are given on the x-axis. The mRNA levels are expressed relative to the mRNA level of the drug-sensitive
parental cell line Slou. The mRNA level of the parental cell line is 100% by definition. For the clones that were analysed in at least
three independently isolated RNA preparations assayed in independent experiments, the mean mRNA (%) ± s.d. (error bar) is
given. See also Table II for the ten clones analysed in detail.
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- _Table II Topoisomerase IIa and MDR1 mRNA levels of
representative doxorubicin-selected SW-1573 cell lines and clone Slrib
as determined by RNAse protection
Topo IImRNA MDRI mRNA
Cell line level (%)O level (%)'
25.10 70 14 36 + 13b
25.26 58+ 18b 17 3b
5R30 46 5b 6± lb
30.3A 13±2b 23 llb
30.10 56 38 18 14b
30.12 108 ± 29 34 20b
30.14 49 ± 13b 7 lb
40.3 29 ±l lb 0.8 0.8b
40.8 123±4 6 2b
40.10 45 lob 15 llb
IRSOb 13 3b 15± 6b
Slrib ND 13 7b
aThe mRNA level ofthe parental cell line is 100% by definition. The
data were obtained from three independently isolated RNA
preparations assayed in three independent experiments and are
presented as the mean mRNA (%) ± s.d. bThe mRNA level is
significantly reduced compared with the level of the parental cell line
with at least 95% confidence.
between the pHi of the resistant and the parental cell lines
(data not shown). This excludes a contribution of a pH,
increase to the decreased accumulation of the weak base
daunorubicin in the resistant cell lines. In addition, no
differences in DNA content were found between any of the
resistant clones and the parental cells (data not shown),
excluding the possibility that the decrease in daunorubicin
accumulation was due to a decreased amount of target DNA
in the resistant cells.
Most resistant variants also accumulated less vincristine
than the parental cells (Table III). This vincristine accumula-
tion is corrected for differences in cell volume between resis-
tant and parental cells as an increase in cell size might result
in an increase in vincristine uptake and prevent the detection
of an accumulation defect. A significant decrease in vincris-
tine accumulation was detected for the clones isolated at the
higher doxorubicin concentrations and a tendency towards
decreased vincristine accumulation was found for the clones
isolated at lower doxorubicin concentrations (25 nM/30 nM).
Two clones, 5R30 and 25.26, showed no vincristine accumu-
lation defect. Clone 5R30 was also not resistant to vincris-
tine. Clone 25.26, however, is unusual in that it has a clear
MDR phenotype despite its lack of a detectable accumula-
tion defect for both daunorubicin or vincristine. There are
two possibilities for the altered behaviour of clone 25.26. The
first explanation is that this clone is multidrug resistant
owing to a single mutation, and resistance in this clone is
also due to a restricted access of drug to target. The alterna-
tive explanation would be that clone 25.26 carries two
independent mechanisms for drug resistance, one conferring
resistance to doxorubicin, like 5R30, and a second mutation
conferring resistance to vincristine. This mutation, however,
would have occurred in the absence of the selecting drug. In
view of the very low frequency of spontaneously arising
vincristine-resistant clones, we consider the scenario with two
independent mutations highly unlikely. We assume that resis-
tance in 25.26 is due to the restriction of drug to target,
which somehow does not show up in our drug accumulation
assays. Therefore, we have not included this clone in the
statistical analysis regarding drug accumulation described
below.
The results in Table II show that the resistance of the new
clones is associated with the decreased drug accumulation in
a qualitative sense. To analyse whether the level of drug
accumulation also correlated with the degree of drug resis-
tance in a quantitative sense, correlation coefficients were
calculated for the parental cell line Slou and its resistant
derivatives. The unusual clone 25.26 was excluded from this
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analysis. A correlation coefficient of - 0.76 was obtained for
vincristine accumulation and resistance, indicating that resis-
tance is due to reduced drug accumulation (P<0.01). For
the relation between reduced daunorubicin accumulation and
resistance to the related anthracycline doxorubicin a low,
non-significant, correlation coefficient of - 0.44 was found
(P>0.05). This suggests that additional factors, such as
alterations of topo IIa, affect doxorubicin resistance in these
clones.
MDR1 P-gp mRNA levels are not increased in the SW-1573
clones with low-level MDR
MDR] P-gp mRNA levels were measured in all 34
doxorubicin-selected clones by a RNAse protection assay (see
Figure 1 for all clones and Table II for the ten clones
analysed in detail). None of the resistant clones had elevated
MDR] P-gp mRNA levels. On the contrary, nearly all clones
showed some degree of MDR] mRNA reduction, whereas a
decrease of MDRJ mRNA levels of more than 50% was
detectable in seven out of the ten clones isolated at 25 nM
doxorubicin, in 14 out of the 16 clones selected at 30 nM and
in all eight clones selected at 40 nM.
The reduction ofMDR1 P-gp mRNA levels correlates with
reduced vincristine accumulation
All ten doxorubicin-selected clones analysed, showed a
significant reduction of MDR] P-gp mRNA (Table II). To
test whether a quantitative relation with drug resistance was
present, correlation coefficients were calculated. The reduc-
tion of MDR] P-gp mRNA level and vincristine resistance
showed a low, non-significant, correlation coefficient of
- 0.47 (P>0.05). The reduction of MDR] P-gp mRNA
level and decreased vincristine accumulation showed a non-
significant correlation coefficient of0.44 (P>0.05). However,
omission of the data for clones 25.26 and 5R30, which do
not show a vincristine accumulation defect, raises this last
value to 0.91 (P<0.01).
Reduction oftopoisomerase IIa gene expression is an
additional event in the development oflow-level doxorubicin
resistance
To determine the frequency of topo IIa mRNA reduction, all
34 doxorubicin-selected clones were analysed in RNAse pro-
tection assays. The topo Ila mRNA levels of the resistant
clones varied from parental levels to less than 20% of paren-
tal levels (see Figure lb and Table II for the ten clones
analysed in detail). The decrease was at least 2-fold in 8 out
of 16 clones isolated at 30 nM doxorubicin and in three out
of seven clones isolated at 40 nM doxorubicin.
Statistical analysis of the data for the ten clones that were
analysed in detail (Table II) showed a significant reduction of
topo IIa levels in six clones (25.26, 5R30, 30.3, 30.14, 40.3,
40.10). This suggests that low doxorubicin concentrations can
select for cells with lowered topo lla mRNA levels.
FACS analysis showed no significant differences in cell
cycle distribution between the clones and the parental cell
lines that could account for the observed topo Ia mRNA
reduction and the variation between the clones (data not
shown). The alterations in topo Ila mRNA level were not
due to changes in Zy-actin levels, since similar results were
obtained with a probe for P-glucuronidase as internal stan-
dard in the RNAse protection experiments (data not shown).
The only exception was clone 40.8, which had an increased
cell size and increased ratio of y-actin to P-glucuronidase
mRNA in the absence of a decreased topo IIaE mRNA level.
MDR clones selected at low levels ofvincristine do not exhibit
the decrease in topoisomerase lIfi mRNA
To test whether a similar type of non-P-gp MDR could be
obtained with vincristine as with doxorubicin, we selected an
additional set of clones in a single step with 20 or 25 nMAltered MRP is associated with MDR
EWHM Eijdems etal
302
Table III Daunorubicin and vincristine accumulation in SW-1573 clones selected at
low doxorubicin or vincristine concentration
Daunorubicin accumulationa
Control Digitonin Vincristine accumulationa
Cell line pmol10-6 cells % pmol106 cells pmol106 cells %
Doxorubicin-selected
Slou 215 11 100 207 30 21.1 6.7 100
IR50b 146 27c 68 198 41c 11.1 3.9c 52
25.10 180±31c 84 239 19c 14.7±4.8 70
25.26 196 22 91 196 40 26.5 5.9 125
5R30 156±25c 72 215±42c 19.8±0.5 94
30.3A 130 23c 60 221 51c 11.6 3.7c 55
30.10 156 15c 72 258 16c 12.3 6.4 58
30.12 165 19c 77 208 16c 13.8 4.1 65
30.14 182 26c 85 208 50 9.1 2.6c 43
40.3 142 25c 66 195 34c 4.13 2.0c 20
40.8 202 29 94 250 32c 11.4 3.7c 54
40.10 172 29c 80 230 21c 10.3 3.3c 49
Vincristine-selected
Slou" 331 12 100 290 43 27.9 8.6 100
20V2 175 29c 53 284 36c 7.4 1.7c 30
25V4 154 13c 47 296 21c 7.2 1.7c 28
aThe data are from 3-8 independentexperiments eachperformed inquadruplicate.
The mean accumulation ± s.d. is given. bThe vincristine accumulation iscorrected for
differencesincellvolumecomparedwiththeparentalcelllineasmeasuredbyaCoulter
counter calibrated with microbeads. The standard deviation is obtained from the
standard deviations of both the vincristine accumulation and the cell volume. 'The
accumulation differs significantly from thatin the Sloucells ortheaccumulation after
addition of digitonin differs significantly from that without addition of digitonin
(P<0.05) according to theunpaired Student's t-test. dAs thedrugaccumulation data
for the doxorubicin- and for the vincristine-selected cell lines were determined in
independentexperiments, thedrugaccumulation ofthedrug-sensitiveparentalcellline
for both data sets is given.
vincristine (ICIo of the parental cell line is 2.5 nM). These
were the lowest concentrations that still fully eliminated
parental background clones. After 6 months of selection, six
clones were isolated and cultured in the presence of vincris-
tine. The analysis of these clones is summarised in Figure 2
and Tables I and IV. The vincristine-selected clones resemble
their doxorubicin-selected counterparts in several characteris-
tics, i.e. resistance to both doxorubicin and vincristine (Table
I), decreased drug accumulation (Table III) and a reduced
MDRJ P-gp mRNA level (Figure 2). However, they differ
from the doxorubicin-selected clones in two properties: they
lack the reduced topo IIa mRNA level (Figure 2) and they
have a much higher vincristine than doxorubicin resistance
(Table I). Whereas the average ratio doxorubicin/vincristine
resistance was 1.6 (range 0.8-4.0) for the ten doxorubicin-
selected clones, it was only 0.3 (range 0.2-0.3) for the six
vincristine-selected ones (Table I).
The reduction ofMDR1 P-gp mRNA does not contribute to
drug resistance
We showed that the reduction of MDR] P-gp mRNA was
co-transferred with the MDR phenotype in somatic cell
fusion experiments (Eijdems et al., 1992) and was present in
all MDR SW-1573 cells in this study (Figures I and 2, Table
II). The MDR] P-gp extrudes drugs from cells and one
would therfore not expect a decrease in MDR] expression to
increase resistance. To exclude exotic indirect effects, we
artificially reduced the MDR] in the parental drug-sensitive
cells by transfection of a hammerhead ribozyme specific for
MDR] (Kobayashi et al., 1993, 1994). Transfected cells were
selected for G-418 resistance, as a neomycin phosphotrans-
ferase gene was present in the expression vector. One of ten
G-418-resistant subclones, clone Slrib, showed a reduced
MDR] mRNA level similar to that of the SW-1573 non-P-gp
MDR cells (Table II), but no detectable decrease or increase
of sensitivity to doxorubicin, vincristine or VP16-213 was
found for this clone in clonogenic survival assays (data not
shown). These results indicate that, despite the observed
down-regulation of MDR] mRNA in the MDR cell lines,
reduced MDR] mRNA levels do not contribute to drug
resistance in the SW-1573 cells.
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Figure 2 RNAse protection assays to quantify MDR] P-gp,
MRP and topoisomerase lla mRNA levels in the SW-1573 clones
selected with vincristine. The vincristine concentration used for
selection (nM) is used for nomenclature, followed by an identify-
ing clone number. For comparison, RNA of the original non-P-
gp MDR cell line 1R50b was also assayed. Ten micrograms of
total cytoplasmic RNA from each SW-1573 derivative was used.
The y-actin signal was comparable for the independent
experiments. On a longer exposure a very faint band of MDR]
mRNA signal was detectable in the vincristine-selected clones and
was similar to the signal in the IR50b cell line.
MRP mRNA levels in the resistant SW-1573 clones
All new MDR clones showed a slight increase in MRP
mRNA level (Figures 2 and 3, Table IV). For most individ-
ual clones this small increase was not statistically significant,
as also observed in initial experiments with the resistant cellline IR50b (Zaman et al., 1993). We observed large varia-
tions in independently isolated RNA preparations, illustrated
by the standard deviations in Table IV, e.g. 1R50b
129% ± 79. Only two individual clones, 30.12 and 30.3M,
showed a significant increase in MRP mRNA (with at least
95% confidence; Table IV and Figure 3). In 30.3M, obtained
by continued doxorubicin selection of 30.3A, this increase
was due to transcriptional activation of the MRP gene
(Eijdems et al., 1995a), which was accompanied by an inc-
rease in both doxorubicin and vincristine resistance com-
pared with 30.3A (Table I). This suggests that MRP can be
involved in low-level drug resistance in the SW-1573 cell
lines. Despite large variability in MRP mRNA levels in the
individual clones, all clones taken as a group had a
significant increase of MRP mRNA level relative to the
parental cells (t-test, P<0.01).
An alteredform ofMRP in the MDR SW-1573 cells
To test whether the slight increase in MRP mRNA found in
the resistant variants was translated into an increased level of
MRP protein, we analysed the level of MRP in these variants
Altered MRP is associated with MDR
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by immunoblotting. Cell extracts were size fractionated by
SDS-PAGE and MRP was detected on blots with a mono-
clonal antibody raised against a MRP fusion protein (Flens
et al., 1994). Figure 4a and b shows no major increase in
MRP levels in these clones, in line with the mRNA results.
However, the resistant clones contained MRP with an aber-
rant migration pattern in SDS-PAGE. A band with an
a
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TableIV MRPmRNAlevelsoflow-resistant MDRSW-1573celllines
selected with doxorubicin or vincristine
Cell line MRP mRNA level (%)'
Doxorubicin-selected
25.10 161 ± 102
30.12 218 82b
40.3 171 57
lR5Ob 129 79
30.3M 292 ± 64b
Vincristine-selected
20V2 198 86
25V4 189 73
aThe MRPmRNA oftheparentalcell line is 100% bydefinition. The
data were obtained from three independently isolated RNA
preparations assayed in three independent experiments and are
presented as the mean mRNA (%) ± s.d. 'The mRNA level differs
significantly from that of the parental cell line with at least 95%
confidence.
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Figure 3 RNAse protection assay to quantify MRP mRNA
levels in the SW-1573 clones selected with doxorubicin. The
doxorubicin concentration used for selection (nM) is used for the
nomenclature, followed by an identifying clone number. For
comparison, RNA of the original non-P-gp MDR cell line IR50b
was also assayed. Ten micrograms of total cytoplasmic RNA
from each SW-1573 derivative was used. The positions of the
protected fragments of MRP and y-actin mRNA as well as the
size (nucleotides) of the molecular weight markers are indicated
(M).
Figure 4 Western blot analysis of MRP in SW-1573 cells. (a and
b) MRP in total cell lysates of drug-sensitive cell line Slou and
low-resistance SW-1573 cell lines. The cell lines were selected with
doxorubicin (25.10, 30.3A, 30.3M, 30.12, 40.3 and lR5Ob) or
vincristine (20V2 and 25V4), or were derived by somatic cell
fusion between cell line IR5Ob and drug-sensitive, parental cell
line Slou (F6.1 and F6.3). (c) Crude cellular membrane fractions
of Slou, lR50b, 30.3M and 20V2, incubated in the absence (-)
or presence (+) of N-glycanase. The protein samples (30pg of
protein per lane for a and b, and 20jg for c) were size frac-
tionated in a 7.5% polyacrylamide gel containing 0.5% SDS,
transferred to a nitrocellulose membrane and MRP was detected
by incubation with monoclonal antibody MRPrl. The size (kDa)
and position of molecular weight markers are indicated.
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apparent molecular mass of 190-200 kDa was present,
whereas parental MRP runs at 180 kDa (Figure 4a and b).
The relative amounts of the 180 kDa and the 190-200 kDa
forms of MRP varied somewhat in different clones. The
increase in resistance level in cell line 30.3M compared with
30.3A (Table I) was accompanied by a nearly complete
replacement of the 180 kDa protein by the 190 -200 kDa
protein (Figure 4a). The protein with altered mobility was
also detectable in the non-P-gp MDR cell hybrids F6.1 and
F6.3 (Figure 4b), which were derived by somatic cell fusion
of the non-P-gp MDR cell line 1R5Ob with drug-sensitive cell
line Slou (Eijdems et al., 1992). This shows that the presence
of the 190-200 kDa MRP protein is linked to the non-P-gp
MDR phenotype in the SW-1573-derived cell lines.
To analyse the nature of the altered behaviour of MRP on
SDS-PAGE, crude cellular membrane fractions of the
multidrug-resistant cell lines 1R5Ob, 30.3M (doxorubicin
selected) and 20V2 (vincristine selected) were analysed
(Figure 4c). In the membrane fractions, a single MRP band
with a molecular weight in the range of 190-200 kDa was
detectable in the resistant cells, in contrast to the 180 kDa
protein detectable in the parental, drug-sensitive cell line
Slou. Similar to the results obtained with total cell lysates,
no major increase in the amount of MRP and protein was
detectable in the resistant cell lines (1R50b, 20V2). Only cell
line 30.3M, which has a 3-fold elevated MRP mRNA, also
showed an increase of MRP epitopes in the membrane frac-
tions.
Treatment of the crude cellular membrane fractions with
N-glycanase, which removes N-linked oligosaccharides, resul-
ted in the appearance of a single band in the range of
150kDa in both the parental and in the resistant cell lines
(Figure 4c). This indicates that the altered mobility of MRP
in the resistant cell lines is due to differences in post-
translational modification and not to major differences in the
protein backbone.
Treatment of purified membrane fractions with endoglyco-
sidase H (Endo H), which removes high-mannose oligosac-
charides, did not affect the mobility of MRP either in the
resistant cell lines or in the drug-sensitive cell line Slou (data
not shown). Removal of sialic acid with neuraminidase
reduced the size of MRP protein in both the drug-resistant
and the drug-sensitive cells to the same extent and did not
alter the difference in mobility (data not shown). These
results demonstrate that the 180kDa and the 190-200kDa
MRP proteins both contain complex oligosaccharides and
must have passed the medial Golgi compartment and reached
the trans-Golgi network.
Discussion
We have analysed a large set ofdrug-resistant variants of the
human lung cancer line SW-1573, selected with low concen-
trations of either doxorubicin or vincristine. We found that
the predominant type ofresistance is a form of MDR charac-
terised by reduced drug accumulation and decreased MDR]
P-gp mRNA levels. Since the degree of resistance correlates
with the extent to which drug accumulation is diminished, it
seems likely that the lowered intracellular drug concentra-
tions are mainly responsible for resistance in these variants.
A diminished drug accumulation has also been observed in
other non-P-gp MDR cell lines (reviewed by Cole, 1992), the
H69/AR cell line being the only exception (Cole et al., 1991).
Overexpression of the MRP gene can confer multidrug
resistance associated with reduced drug accumulation in
human HeLa cells (Grant et al., 1994) and SW-1573 cells
(Zaman et al., 1994). In several non-P-gp MDR cell lines a
role for overexpression of MRP was suggested as well
(Krishnamachary and Center, 1993; Slovak et al., 1993;
Zaman et al., 1993; Barrand et al., 1994; Schneider et al.,
1994). The MRP mRNA and MRP protein levels in most
clones isolated in this study were increased at most 2-fold. At
first sight, it seems unlikely that this could account for the
complete MDR phenotype in these SW-1573 cells. However,
our finding that an altered form of MRP is present in all our
non-P-gp MDR clones and that this altered form co-
segregates with the non-P-gp MDR trait in somatic cell
fusion experiments strongly indicates that MRP is involved
in the non-P-gp phenotype of these clones. To test this more
directly, we are constructing a ribozyme directed against
MRP mRNA.
The precise nature of the alteration of MRP resulting in
altered migration in SDS-PAGE gels is not yet known. Our
results show that this altered mobility is due to a change in
the MRP-linked complex oligosaccharides. Post-translational
modification is the most plausible explanation. This modi-
fication could either be directly responsible for MDR, e.g.
result in a more active MRP drug pump, or it could be a
consequence of other alterations affecting MRP, such as
altered routing in the Golgi apparatus. Minor changes in the
primary structure of MRP cannot be excluded yet.
A remarkable feature of the non-P-gp MDR SW-1573
clones is the paradoxical decrease of MDR] mRNA levels.
This was also reported for the H69-AR cell line (Cole et al.,
1991), the non-P-gp MDR cell line from which the MRP
gene was isolated (Cole et al., 1992). Although it is hard to
believe that a decrease in MDRJ P-glycoprotein could result
in an increased drug extrusion, the theoretical possibility
existed that P-glycoprotein was extruding an endogenous
compound required to induce the non-P-gp MDR mecha-
nism in SW-1573 cells. Our ribozyme experiment excludes
this far-fetched possibility. Hence, the down-regulation of
MDRI does not cause MDR in our resistant clones, but is a
side-effect of the mutation causing the non-P-gp phenotype.
In view of the alteration of MRP in the SW-1573 cells, the
decrease in MDRJ mRNA could be an indirect effect of the
post-translational modification of a regulator of MDR]
expression. The absence of increased MDR] expression in the
non-P-gp MDR cell is not due to the inability of the SW-
1573 cells to activate the MDR] gene since we have shown
that SW-1573 cells selected for higher levels of resistance
invariably increase their expression of MDR] (Baas et al.,
1990).
The non-P-gp MDR phenotype with altered MRP, reduced
drug uptake and reduced MDR] mRNA was obtained both
with doxorubicin and vincristine selection. However, the
resistance spectra of the two types of clones differed (Table
I). This suggests that cells may activate multiple resistance
mechanisms, even at these low levels of selection. In the case
of doxorubicin selection, the supplementary resistance
mechanism probably consists of alterations in topo Ila. Most
of the MDR variants selected for doxorubicin resistance
contained decreased topo Ilm mRNA levels, and the clones
with normal mRNA level may nevertheless contain decreased
topo II enzyme activity (Eijdems et al., 1995b). In the case of
vincristine selection, we have no clue as to the mechanism
that contributes to the relatively high vincristine resistance.
Our experiments show that low-level resistance associated
with altered MRP arises with high frequency in SW-1573
cells. Precise estimates of this frequency are not available, as
the sensitive cells continue to divide slowly during mutant
selection at low drug concentration. It is clearly much higher,
however, than the activation of MDRJ, which occurs at a
frequency of 1-2 x 10-6 per cell in SW-1573 when higher
drug concentrations are used for selection (Eijdems et al.,
1992, and unpublished results). We infer from our results
that resistance associated with altered MRP only protects
against relatively low levels of resistance. This follows from
the association of this type of resistance with other forms of
low-level resistance, topo II alterations or unknown, and
from the fact that selection for higher levels of resistance
results either in an activation of MDR] or in a transcrip-
tional activation of MRP. The only clear example of MRP
activation is clone 30.3M, which has a 3-fold increase in
MRP mRNA. We have recently shown by RNA run-on
experiments that this is due to increased transcription of
MRP (Eijdems et al., 1995b).
In conclusion, we have shown that in the SW-1573 lung
cancer cell line low levels of two different types of drug selectAltered MRP is associated with MDR
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for altered MRP accompanied by reduced drug accumulation
and concomitant multidrug resistance. Although this MDR
phenotype correlated well with reduced MDRJ mRNA, we
excluded a contribution of this reduction to drug resistance.
Our results also show that, even at the low drug concentra-
tions used, multiple resistance mechanisms may coexist in
resistant clones.
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